Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
ASN 2026
Effect of Finerenone on Risk Biomarkers of CKD Progression: A FIND-CKD Analysis
- In patients with biopsy-confirmed nondiabetic CKD, KIM-1 and various fibrosis-associated markers (CSPG4, MMP7, LAYN) were downregulated by finerenone vs placebo. Renin was the most upregulated protein among >2,500 detected.
- Finerenone shifted risk biomarkers towards a generally beneficial profile.
- KIM-1 and LAYN were identified as top risk biomarkers for CKD progression across 4 trials and revealed a sustained treatment response to finerenone in FIND-CKD.
- The overall biomarker profile after finerenone treatment is consistent with amelioration of injury & fibrosis and better tubular function. The mechanism of finerenone in glomerular disease affects various nephron compartments.
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
